Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases

References

• Orlowski S, Belehradek J, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture – increase of the cyto-toxicity of anticancer drugs. Biochem. Pharmacol.37(24), 4727–4733 (1988).
   PubMed Web of Science ®Google Scholar
• Mir LM, Orlowski S, Belehradek J, Paoletti C. Electrochemotherapy potentiation of antitumor effect of bleomycin by local electric pulses. Eur. J. Cancer27(1), 68–72 (1991).
   PubMed Web of Science ®Google Scholar
• Sersa G, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy of tumours. Radiol. Oncol.40(3), 163–174 (2006).
   Google Scholar
• Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. EJC Suppl.4(11), 52–59 (2006).
   Google Scholar
• Marty M, Sersa G, Garbay JR et al. Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl.4(11), 3–13 (2006).
   Google Scholar
• Quaglino P, Mortera C, Osella-Abate S et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann. Surg. Oncol.15(8), 2215–2222 (2008).
   PubMed Web of Science ®Google Scholar
• Mir LM, Gehl J, Sersa G et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. EJC Suppl.4(11), 14–25 (2006).
   Web of Science ®Google Scholar
• Mir LM, Devauchelle P, Quintin-Colonna F et al. First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br. J. Cancer76(12), 1617–1622 (1997).
   PubMed Web of Science ®Google Scholar
• Rols MP, Tamzali Y, Teissie J. Electrochemotherapy of horses. A preliminary clinical report. Bioelectrochemistry55(1–2), 101–105 (2002).
   PubMedGoogle Scholar
• Tozon N, Kodre V, Sersa G, Cemazar M. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res.25(2A), 839–845 (2005).
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Vincenzi B, Baldi F, Citro G, Baldi A. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res.26(6B), 4585–4589 (2006).
   PubMedGoogle Scholar
• Spugnini EP, Baldi A, Vincenzi B et al. Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother. Pharmacol.59(3), 375–381 (2007).
   PubMedGoogle Scholar
• Cemazar M, Tamzali Y, Sersa G et al. Electrochemotherapy in veterinary oncology. J. Vet. Intern. Med.22(4), 826–831 (2008).
   PubMed Web of Science ®Google Scholar
• Kodre V, Cemazar M, Pecar J, Sersa G, Cor A, Tozon N. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo23(1), 55–62 (2009).
   PubMedGoogle Scholar
• Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope111(1), 52–56 (2001).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, Cristobal-Martinez L, Gonzalez-Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin. Arch. Med. Res.32(4), 273–276 (2001).
   PubMed Web of Science ®Google Scholar
• Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res.10(5), 468–474 (2000).
   PubMed Web of Science ®Google Scholar
• Burian M, Formanek M, Regele H. Electroporation therapy in head and neck cancer. Acta Otolaryngol. (Stockh.)123(2), 264–268 (2003).
   PubMed Web of Science ®Google Scholar
• Bloom DC, Goldfarb PM. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur. J. Surg. Oncol.31(9), 1029–1035 (2005).
   PubMed Web of Science ®Google Scholar
• Byrne CM, Thompson JF, Johnston H et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res.15(1), 45–51 (2005).
   PubMed Web of Science ®Google Scholar
• Tijink BM, De Bree R, Van D, Leemans CR. How we do it: chemo-electroporation in the head and neck for otherwise untreatable patients. Clin. Otolaryngol.31(5), 447–451 (2006).
   PubMed Web of Science ®Google Scholar
• Sadadcharam M, Soden DM, O’Sullivan GC. Electrochemotherapy: an emerging cancer treatment. Intl. J. Hyperthermia24(3), 263–273 (2008).
   PubMed Web of Science ®Google Scholar
• Möller MG, Salwa S, Soden DM, O’Sullivan GC. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Exp. Rev. Anticancer Ther.9(11), 1611–1630 (2009).
   PubMed Web of Science ®Google Scholar
• Heller R, Gilbert R, Jaroszeski MJ. Clinical applications of electrochemotherapy. Adv. Drug Deliv. Rev.35(1), 119–129 (1999).
   PubMed Web of Science ®Google Scholar
• Heller R, Jaroszeski MJ, Reintgen DS et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer83(1), 148–157 (1998).
   PubMed Web of Science ®Google Scholar
• Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat. Rev.29(5), 371–387 (2003).
   PubMed Web of Science ®Google Scholar
• Testori A, Rutkowski P, Marsden J et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann. Oncol.20, 22–29 (2009).
   Google Scholar
• Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim. Biophys. Acta1088(1), 131–134 (1991).
   PubMed Web of Science ®Google Scholar
• Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol.16(2), 168–171 (1998).
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol.16(9), 867–870 (1998).
   PubMed Web of Science ®Google Scholar
• Mir LM, Bureau MF, Gehl J et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl Acad. Sci. USA96(8), 4262–4267 (1999).
   PubMed Web of Science ®Google Scholar
• Satkauskas S, Bureau MF, Puc M et al. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol. Ther.5(2), 133–140 (2002).
   PubMed Web of Science ®Google Scholar
• Satkauskas S, Andre F, Bureau MF, Scherman D, Miklavcic D, Mir LM. Electrophoretic component of electric pulses determines the efficacy of in vivo DNA electrotransfer. Hum. Gene Ther.16(10), 1194–1201 (2005).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? Curr. Pharm. Des.12(29), 3817–3825 (2006).
   PubMed Web of Science ®Google Scholar
• Kanduser M, Miklavcic D, Pavlin M. Mechanisms involved in gene electrotransfer using high- and low-voltage pulses – an in vitro study. Bioelectrochemistry74(2), 265–271 (2009).
   PubMed Web of Science ®Google Scholar
• Neumann E, Schaeferridder M, Wang Y, Hofschneider PH. Gene-transfer into mouse lyoma cells by electroporation in high electric-fields. EMBO J.1(7), 841–845 (1982).
   PubMed Web of Science ®Google Scholar
• Pavselj N, Preat V. DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J. Control Release106(3), 407–415 (2005).
   PubMed Web of Science ®Google Scholar
• Heller LC, Heller R. In vivo electroporation for gene therapy. Hum. Gene Ther.17(9), 890–897 (2006).
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr. Gene Ther.6(2), 243–273 (2006).
   PubMed Web of Science ®Google Scholar
• Daud AI, DeConti RC, Andrews S et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol.26(36), 5896–5903 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Sakere B, Bernat C, Andre F et al. A study of the immunological response to tumor ablation with irreversible electroporation. Technol. Cancer Res. Treat.6(4), 301–305 (2007).
   PubMed Web of Science ®Google Scholar
• Al-Sakere B, Andre F, Bernat C et al. Tumor ablation with irreversible electroporation. PLoS ONE2(11), e1135 (2007).
   PubMed Web of Science ®Google Scholar
• Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol. Cancer Res. Treat.4(6), 699–705 (2005).
   PubMed Web of Science ®Google Scholar
• Puc M, Rebersek S, Miklavcic D. Requirements for a clinical electrochemotherapy device – electroporator. Radiol. Oncol.31, 816–827 (1997).
   Google Scholar
• Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur. J. Surg. Oncol.34(2), 232–240 (2008).
   PubMed Web of Science ®Google Scholar
• Miklavcic D, Pucihar G, Pavlovec M et al. The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo for a potential use in clinical electrochemotherapy. Bioelectrochemistry65(2), 121–128 (2005).
   PubMed Web of Science ®Google Scholar
• Snoj M, Cemazar M, Kolar BS, Sersa G. Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy. Croat. Med. J.48(3), 391–395 (2007).
   PubMed Web of Science ®Google Scholar
• Miklavcic D, Semrov D, Mekid H, Mir LM. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim. Biophys. Acta Gen. Subj.1523(1), 73–83 (2000).
   PubMed Web of Science ®Google Scholar
• Corovic S, Pavlin M, Miklavcic D. Analytical and numerical quantification and comparison of the local electric field in the tissue for different electrode configurations. Biomed. Eng. Online6, 37 (2007).
   PubMed Web of Science ®Google Scholar
• Corovic S, Zupanic A, Miklavcic D. Numerical modeling and optimization of electric field distribution in subcutaneous tumor treated with electrochemotherapy using needle electrodes. IEEE Trans. Plasma Sci.36(4), 1665–1672 (2008).
   Web of Science ®Google Scholar
• Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. EJC Suppl.4(11), 45–51 (2006).
   Google Scholar
• Sel D, Cukjati D, Batiuskaite D, Slivnik T, Mir LM, Miklavcic D. Sequential finite element model of tissue electropermeabilization. IEEE Trans. Biomed. Eng.52(5), 816–827 (2005).
   PubMed Web of Science ®Google Scholar
• Zupanic A, Corovic S, Miklavcic D. Optimization of electrode position and electric pulse amplitude in electrochemotherapy. Radiol. Oncol.42(2), 93–101 (2008).
   Google Scholar
• Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res.55(15), 3450–3455 (1995).
   PubMed Web of Science ®Google Scholar
• Domenge C, Orlowski S, Luboinski B et al. Antitumor electrochemotherapy – new advances in the clinical protocol. Cancer77(5), 956–963 (1996).
   PubMed Web of Science ®Google Scholar
• Heller R, Jaroszeski M, Perrott R, Messina J, Gilbert R. Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res.7(1), 10–18 (1997).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs9(6), 525–530 (1998).
   PubMed Web of Science ®Google Scholar
• Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs11(3), 201–208 (2000).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br. J. Cancer84(4), 565–570 (2001).
   PubMed Web of Science ®Google Scholar
• Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv. Drug Delivery Rev.35(1), 107–118 (1999).
   PubMed Web of Science ®Google Scholar
• Belehradek J, Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim. Biophys. Acta Biomembr.1190(1), 155–163 (1994).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br. J. Cancer79(9–10), 1386–1391 (1999).
   PubMedGoogle Scholar
• Mir LM, Orlowski S, Poddevin B, Belehradek J. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur. Cytokine Netw.3(3), 331–334 (1992).
   PubMedGoogle Scholar
• Sersa G, Cemazar M, Menart V, GabercPorekar V, Miklavcic D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-α on SA-1 tumors in mice. Cancer Lett.116(1), 85–92 (1997).
   PubMed Web of Science ®Google Scholar
• Sersa G, Miklavcic D, Cemazar M, Belehradek J, Jarm T, Mir LM. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochem. Bioenerg.43, 279–283 (1997).
   Web of Science ®Google Scholar
• Sersa G, Jarm T, Kotnik T et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br. J. Cancer98(2), 388–398 (2008).
   PubMed Web of Science ®Google Scholar
• Sersa G, Cemazar M, Miklavcic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res.19(5B), 4017–4022 (1999).
   PubMed Web of Science ®Google Scholar
• Mir LM, Roth C, Orlowski S et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J. Immunother.17(1), 30–38 (1995).
   PubMed Web of Science ®Google Scholar
• Heller L, Pottinger C, Jaroszeski M-L, Gilbert R, Heller R. In vivo electroporation of plasmids encoding GM-CFS or interleukin-2 into exisiting B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res.10, 577–583 (2000).
   PubMed Web of Science ®Google Scholar
• Sersa G, Beravs K, Cemazar M, Miklavcic D, Demsar F. Contrast enhanced MRI assessment of tumor blood volume after application of electric pulses. Electro. Magnetobiol.17, 299–306 (1998).
   Google Scholar
• Ramirez LH, Orlowski S, An D et al. Electrochemotherapy on liver tumours in rabbits. Br. J. Cancer77(12), 2104–2111 (1998).
   PubMed Web of Science ®Google Scholar
• Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by application of electric pulses. Eur. J. Cancer35(4), 672–677 (1999).
   PubMed Web of Science ®Google Scholar
• Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim. Biophys. Acta Gen. Subj.1569(1–3), 51–58 (2002).
   PubMed Web of Science ®Google Scholar
• Dujardin N, Staes E, Kalia Y, Clarys P, Guy R, Preat V. In vivo assessment of skin electroporation using square wave pulses. J. Control. Release79(1–3), 219–227 (2002).
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev.6(4), 559–593 (1987).
   PubMed Web of Science ®Google Scholar
• Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol.17(5), 869–879 (2000).
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat. Rev. Cancer5(6), 423–435 (2005).
   PubMed Web of Science ®Google Scholar
• Folkman J. Opinion – angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov.6(4), 273–286 (2007).
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumor blood flow: current status and future directions. Semin. Radiat. Oncol.8(3), 151–163 (1998).
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res.335(1), 241–248 (2009).
   PubMed Web of Science ®Google Scholar
• Sersa G, Krzic M, Sentjurc M et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br. J. Cancer87(9), 1047–1054 (2002).
   PubMed Web of Science ®Google Scholar
• Sersa G, Cemazar M, Miklavcic D. Tumor blood flow modifying effects of electrochemotherapy: a potential vascular targeted mechanism. Radiol. Oncol.37(1), 43–48 (2003).
   Google Scholar
• Ivanusa T, Beravs K, Cemazar M, Jevtic V, Demsar F, Sersa G. MRI macromolecular contrast agents as indicators of changed tumor blood flow. Radiol. Oncol.35(2), 139–147 (2001).
   Google Scholar
• Jarm T, Cemazar M, Sersa G. Tumor blood flow-modifying effects of electroporation and electrochemotherapy – experimental evidence and implications for the therapy. In: Advanced Electroporation Techniques in Biology and Medicine. Pakhomov, AG, Miklavcic D, Markov MS (Eds). CRC Press, USA 401–424 (2010).
   Google Scholar
• Pavselj N, Bregar Z, Cukjati D, Batiuskaite D, Mir LM, Miklavcic D. The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. IEEE Trans. Biomed. Eng.52(8), 1373–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Kanthou C, Kranjc S, Sersa G, Tozer G, Zupanic A, Cemazar M. The endothelial cytoskeleton as a target of electroporation-based therapies. Mol. Cancer Ther.5(12), 3145–3152 (2006).
   PubMed Web of Science ®Google Scholar
• Usaj M, Trontelj K, Hudej R, Kanduser M, Miklavcic D. Cell size dynamics and viability of cells exposed to hypotonic treatment and electroporation for electrofusion optimization. Radiol. Oncol.43(2), 108–119 (2009).
   Web of Science ®Google Scholar
• Valic B, Golzio M, Pavlin M et al. Effect of electric field induced transmembrane potential on spheroidal cells: theory and experiment. Eur. Biophys. J. Biophys. Lett.32(6), 519–528 (2003).
   PubMed Web of Science ®Google Scholar
• Sentjurc M, Cemazar M, Sersa G. EPR oximetry of tumors in vivo in cancer therapy. Spectrochim. Acta A Mol. Biomol. Spectrosc.60, 1379–1385 (2004).
   PubMedGoogle Scholar
• Jarm T, Cemazar M, Steinberg F, Streffer C, Sersa G, Miklavcic D. Perturbation of blood how as a mechanism of anti-tumour action of direct current electrotherapy. Physiol. Meas.24(1), 75–90 (2003).
   PubMedGoogle Scholar
• Jarm T, Sersa G, Miklavcic D. Oxygenation and blood flow in tumors treated with hydralazine: evaluation with a novel luminescence-based optic sensor. Technol. Health Care10, 363–380 (2002).
   PubMedGoogle Scholar
• Cör A, Cemazar M, Plazar N, Sersa G. Comparison between hypoxic markers pimonidazole and glucose transporter 1 (Glut-1) in murine fibrosarcoma tumours after electrochemotherapy. Radiol. Oncol.43(3), 195–202 (2009).
   Google Scholar
• Cemazar M, Parkins CS, Holder AL, Kranjc S, Chaplin DJ, Sersa G. Cytotoxicity of bioreductive drug tirapazamine is increased by application of electric pulses in SA-1 tumours in mice. Anticancer Res.21(2A), 1151–1156 (2001).
   PubMedGoogle Scholar
• Larkin JO, Collins CG, Aarons S et al. Electrochemotherapy – aspects of preclinical development and early clinical experience. Ann. Surg.245(3), 469–479 (2007).
   PubMed Web of Science ®Google Scholar
• Campana LG, Mocellin S, Basso M et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann. Surg. Oncol.16(1), 191–199 (2009).
   PubMed Web of Science ®Google Scholar
• Byrne CM, Thompson JF. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev. Anticancer Ther.6(5), 671–678 (2006).
   PubMed Web of Science ®Google Scholar
• Kubota Y, Mir LM, Nakada T, Sasagawa I, Suzuki H, Aoyama N. Successful treatment of metastatic skin lesions with electrochemotherapy. J. Urol.160(4), 1426–1426 (1998).
   PubMed Web of Science ®Google Scholar
• Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res.10(6), 585–589 (2000).
   PubMed Web of Science ®Google Scholar
• Gehl J, Geertsen PF. Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy. EJC Suppl.4(11), 35–37 (2006).
   Google Scholar
• Snoj M, Cemazar M, Srnovrsnik T, Kosir SP, Sersa G. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori95(3), 398–402 (2009).
   PubMed Web of Science ®Google Scholar
• Fletcher WS, Pommier RF, Lum S, Wilmarth TJ. Surgical treatment of metastatic melanoma. Am. J. Surg.175(5), 413–417 (1998).
   PubMed Web of Science ®Google Scholar
• Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J. Sci. Am.1, 104–105 (1995).
   PubMedGoogle Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, van Geel A, Eggermont AM, Kroon BB. Repeat isolated limb perfusion with TNF a and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur. J. Surg. Oncol.32(3), 318–324 (2006).
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. The palliative value of tumor necrosis factor α-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer106(1), 156–162 (2006).
   PubMed Web of Science ®Google Scholar
• Sasso CM, Hubner C, Wall S. Intraarterial embolization of bleeding melanoma. J. Vasc. Nurs.13(1), 27–28 (1995).
   PubMedGoogle Scholar
• Lavee J, Onik G, Mikus P, Rubinsky B. A novel nonthermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg. Forum10(2), E162–E167 (2007).
   PubMed Web of Science ®Google Scholar
• Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J. Urol.180(6), 2668–2674 (2008).
   PubMed Web of Science ®Google Scholar
• Nuccitelli R, Chen X, Pakhomov AG et al. A new pulsed electric field therapy for melanoma disrupts the tumor’s blood supply and causes complete remission without recurrence. Int. J. Cancer125(2), 438–445 (2009).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Golzio M, Sersa G et al. Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther.16(5), 635–644 (2009).
   PubMedGoogle Scholar
• Andre FM, Gehl J, Sersa G et al. Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin. Hum. Gene Ther.19(11), 1261–1271 (2008).
   PubMed Web of Science ®Google Scholar
• Trochon-Joseph V, Martel-Renoir D, Mir LM et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res.64(6), 2062–2069 (2004).
   PubMed Web of Science ®Google Scholar
• Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G. Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res.23(1A), 275–281 (2003).
   PubMedGoogle Scholar
• Sersa G, Kranjc S, Cemazar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int. J. Radiat. Oncol. Biol. Phys.46(4), 1037–1041 (2000).
   PubMedGoogle Scholar
• Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G. Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. Radiat. Res.172(6), 677–685 (2009).
   PubMedGoogle Scholar
• Pendas S, Jaroszeski MJ, Gilbert R et al. Direct delivery of chemotherapeutic agents for the treatment of hepatomas and sarcomas in rat models. Radiol. Oncol.32, 53–64 (1998).
   Google Scholar
• Metal Complexes in Cancer Chemotherapy. Keppler BK (Ed.). Weinheim, Germany Wiley-VCH (1993).
   Google Scholar
• Sava G, Alessio E, Bergamo A, Mestroni G. Sulfoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumour metastases. In: Biological Inorganic Chemistry 1. Clarke MJ, Sadler PJ (Eds). Springer, Berlin, Germany (1999).
   Google Scholar
• Bicek A, Turel I, Kanduser M, Miklavcic D. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro. Bioelectrochemistry71(2), 113–117 (2007).
   PubMed Web of Science ®Google Scholar
• Hudej R, Turel I, Kanduser M et al. The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. Anticancer Res. (2010) (In press).
   PubMedGoogle Scholar
• Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R. Design of an irreversible electroporation system for clinical use. Technol. Cancer Res. Treat.6(4), 313–320 (2007).
   PubMed Web of Science ®Google Scholar
• Miklavcic D, Snoj M, Zupanic A et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. Biomed. Eng. Online9, 10 (2010).
   PubMed Web of Science ®Google Scholar
• Schmiedl U, Ogan M, Paajanen H et al. Albumin labeled with GD-DTPA as an intravascular, blood pool enhancing agent for MR imaging – biodistribution and imaging studies. Radiology162(1), 205–210 (1987).
   PubMed Web of Science ®Google Scholar
• Demsar F, Roberts TPL, Schwickert HC et al. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution. Magn. Reson. Med.37(2), 236–242 (1997).
   PubMed Web of Science ®Google Scholar
• Sapirstein LA. Regional blood flow by fractional distribution of indicators. Am. J. Physiol.193, 161–168 (1958).
   PubMed Web of Science ®Google Scholar
• Shepherd AP, Öberg PÅ. Laser-Doppler blood flowmetry.Kluwer Academic Publishers, MA, USA (1990).
   Google Scholar
• Delorme S, Krix M. Contrast-enhanced ultrasound for examining tumor biology. Cancer Imaging6(1), 148–152 (2006).
   PubMedGoogle Scholar
• Sersa G, Krzic M, Sentjurc M et al. Reduced tumor oxygenation by treatment with vinblastine. Cancer Res.61(10), 4266–4271 (2001).
   PubMed Web of Science ®Google Scholar
• O’Hara JA, Blumenthal RD, Grinberg OY et al. Response to radioimmunotherapy correlates with tumor pO2 measured by EPR oximetry in human tumor xenografts. Radiat. Res.155(3), 466–473 (2001).
   PubMed Web of Science ®Google Scholar
• Swartz HM, Clarkson RB. The measurement of oxygen in vivo using EPR techniques. Phys. Med. Biol.43(7), 1957–1975 (1998).
   PubMedGoogle Scholar
• Collingridge DR, Young WK, Vojnovic B et al. Measurement of tumor oxygenation: A comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat. Res.147(3), 329–334 (1997).
   PubMed Web of Science ®Google Scholar
• Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors – evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res.51(12), 3316–3322 (1991).
   PubMed Web of Science ®Google Scholar
• Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett.221(2), 225–235 (2005).
   PubMed Web of Science ®Google Scholar
• Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int. J. Radiat. Oncol. Biol. Phys.49, 569–574 (2001).
   PubMedGoogle Scholar
• Chen CH, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1 – interaction between H-ras and hypoxia. J. Biol. Chem.276(12), 9519–9525 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper R, Sarioglu S, Sokmen S et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br. J. Cancer89(5), 870–876 (2003).
   PubMed Web of Science ®Google Scholar